[1]王晓燕,梁 萍,董艳婷.非特异性免疫疗法在支气管哮喘治疗中的应用进展[J].医学信息,2019,(05):57-60.[doi:10.3969/j.issn.1006-1959.2019.05.018]
 WANG Xiao-yan,LIANG Ping,DONG Yan-ting.Progress in the Application of Non-specific Immunotherapy in the Treatment of Bronchial Asthma[J].Medical Information,2019,(05):57-60.[doi:10.3969/j.issn.1006-1959.2019.05.018]





Progress in the Application of Non-specific Immunotherapy in the Treatment of Bronchial Asthma
王晓燕1梁 萍1董艳婷2
(1.北京卫生职业学院相关医学与管理系,北京 100053;2.山西医科大学第二医院呼吸与危重症医学科,山西 太原 030001)
WANG Xiao-yan1LIANG Ping1DONG Yan-ting2
(1.Department of Medicine and Management,Beijing Health Vocational College,Beijing 100053,China;2.Department of Respiratory and Critical Care Medicine,the Second Hospital of Shanxi Medical University,Taiyuan 030001,Shanxi,China)
Bronchial asthmaNon-specific immunotherapyIgE monoclonal antibodyImmunotherapy
Bronchial asthma is one of the common and frequently-occurring diseases of the respiratory system. It is an airway chronic allergic reaction involving various cells and cellular components such as eosinophils, mast cells, T lymphocytes, and neutrophils. Diseases, global morbidity and mortality are rising, seriously affecting public health and the quality of life of patients. The study found that the incidence of bronchial asthma involves immune disorders, and the imbalance of Th1/Th2 cells is an important mechanism of asthma. On this basis, the immunotherapy of bronchial asthma has made some progress. Based on the immunological mechanism of bronchial asthma, this paper The research and application progress of heterosexual immunotherapy in the treatment of bronchial asthma are reviewed in order to provide new directions and ideas for the treatment of bronchial asthma.


[1]Holgate ST.Immune circuits in asthma[J].Curr Opin Pharmacol,2013,13(3):345-350.
[2]Kim Y,Lee S,Kim YS,et al.Regulation of Th1/Th2 cellsin asthma development:a mathematical model[J].Math Biosci Eng,2013,10(4):1095-1133.
[3]Passalacqua G,Bagnasco D,Ferrando M,et al.Current insights in allergen immunotherapy[J].Ann Allergy Asthma Immunol,2018,120(2):152-154.
[4]Froidure A,Mouthuy J,Durham SR,et al.Asthma phenotypes and IgE responses[J].Eur Respir J,2016,47(1):304-319.
[5]Kuhl K,Hanania NA.Targeting IgE in asthma[J].Curr Opin Pulm Med,2012,18(1):1-5.
[6]Chen S,Golam S,Myers J,et al.Systematic literature review of the clinical,humanistic,and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment[J].Curr Med Res,2018,34(12):2075-2088.
[7]Pelaia G,Canonica GW,Matucci A,et al.Targeted therapy in severe asthma today:focus on immunoglobulin E[J].Drug Des Devel Ther,2017(11):1979-1987.
[8]Minami D,Kayatani H,Sato K,et al.Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab[J].Respirol Case Rep,2019,7(1):e00388.
[9]Corren J,Kavati A,Ortiz B,et al.Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma:A systematic literature review[J].Allergy Asthma Proc,2017,38(4):250-263.
[11]Pilon D,Kavati A,Ortiz B,et al.Asthma control,lung function,symptoms,and corticosteroid sparing after omalizumab?initiation in patients with allergic asthma[J].Allergy Asthma Proc,2018,39(2):127-135.
[12]Di DB,Fiorino I,Taurino M,et al.Long-term"real-life"safety of omalizumab in patients with severe uncontrolled asthma:A nine-year study[J].Respiratory Medicine,2017(130):55.
[13]Korn S,Thielen A,Seyfried S,et al.Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany[J].Respiratory Medicine,2009,103(11):1725-1731.
[14]Grimaldi-Bensouda L,Zureik M,Aubier M,et al.Does omalizumab make a difference to the real-life treatment of asthma exacerbations?Results from a large cohort of patients with severe uncontrolled asthma[J].Chest,2013,143(2):398-405.
[15]Jiang XG,Yang XD,Lv Z,et al.Elevated serum levels of TNF-α,IL-8,and ECP can be involved in the development and progression of bronchial asthma[J].Asthma,2018,55(2):111-118.
[16]Brown SD.Brown LA.Stephenson S,et al.Characterization of a high TNF-α phenotype in children with moderate-to-severe asthma[J].J Allergy Clin Immunol,2015,135(6):1651-1654.
[17]Taillé C,Poulet C,Marchand-Adam S,et al.Monoclonal Anti-TNF-αAntibodies for Severe Steroid-Dependent Asthma:A Case Series[J].Open Respir Med J,2013(7): 21-25.
[18]Huang H,Nie W,Qian J,et al.Effects of TNF-α polymorphisms on asthma risk:a systematic review and meta-analysis[J].Investig Allergol Clin Immunol,2014,24(6):406-417.
[19]Menzella F,Lusuardi M,Galeone C,et al.Tailored therapy for severe asthma[J].Multidiscip Respir Med,2015,10(1):1-8.
[20]Patel SS,Casale TB,Cardet JC.Biological therapies for eosinophilic asthma[J].Expert Opin Biol Ther,2018,18(7):747-754.
[21]Barnes PJ.Targeting cytokines to treat asthma and chronic obstructive pulmonary disease[J].Nat Rev Immunol,2018,18(7):454-466.
[22]Bagnasco D,Ferrando M,Varricchi G,et al.A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma[J].Int Arch Allergy Immunol,2016,170(2):122-131.
[23]Majumdar S,Ghosh A,Saha S.Modulating Interleukins and their receptors interactions with small chemicals using in silico approach for asthma[J].Curr Top Med Chem,2018,18(13):1123-1134.
[24]Walsh GM.Anti-IL-4/-13 based therapy in asthma[J].Expert Opin Emerg Drugs,2015,20(3):349-352.
[25]Lim HF,Nair P.Airway inflammation and inflammatory biomarkers[J].Semin Respir Crit Care Med,2018,39(1):56-63.
[26]Strauss RA,Jawhari N.Mepolizumab in the treatment of severe eosinophilic asthma:"results from a physician in the field"[J].Ann Allergy Asthma Immunol,2018,121(1):121-123.
[27]He LL,Zhang L,Jiang L.Efficacy and safety of anti-interleukin-5 therapy in patients with asthma:A pairwise and Bayesian network meta-analysis[J].Int Immunopharmacol,2018(64):223-231.
[28]Tung HY,Li E,Landers C,et al.Advances and Evolving Concepts in Allergic Asthma[J].Semin Respir Crit Care Med,2018,39(1):64-81.
[29]Parulekar AD,Kao CC,Diamant Z,et al.Targeting the interleukin-4 and interleukin-13 pathways in severe asthma:current knowledge and future needs[J].Curr Opin Pulm Med,2018,24(1):50-55.
[30]Seibold MA.Interleukin-13 Stimulation Reveals the Cellular and Functional Plasticity of the Airway Epithelium[J].Ann Am Thorac Soc,2018,15(Supplement_2): S98-S102.
[31]Devos FC,Pollaris L,Cremer J,et al.IL-13 is a central mediator of chemical-induced airway hyperreactivity in mice[J].PLoS One,2017,12(7):e0180690.
[32]Lamour S,Bourne T,Shaw S,et al.Efficacy of an Inhaled IL-13 antibody fragment in a model of chronic asthma[J].Am J Respir Crit Care Med,2018,198(5):610-619.
[33]Bopp T,Taube C.IL-10 and regulatory T cells cooperate in allergen-specific immunotherapy to ameliorate allergic asthma[J].J Immunol,2015,194(3): 887-897.
[34]B?觟hm L,Maxeiner J,Meyer-Martin H,et al.IL-10?and regulatory T cells cooperate in allergen-specific immunotherapy to ameliorate allergic asthma[J].J Immunol,2015,194(3):887-97.
[35]Girodet PO,Nguyen D,Mancini JD,et al.Alternative Macrophage Activation Is Increased in Asthma[J].Am J Respir Cell Mol Biol,2016,55(4):467-475.
[36]Vissers JL,van Esch BC,Hofman GA,et al.Allergen immunotherapy induces a suppressive memory response mediated by IL-10 in a mouse asthma model[J].J Allergy Clin Immunol,2004,113(6):1204-1210.
[37]Kuribayashi K,Kodama T,Okamara H,et al.Effects of post-inhalation treatment with interleukin-12 on airway hyper-reactivity,eosinophilia and interleukin-18 receptor expression ina mouse model of asthma[J].Clin Exp Allergy,2002(32):641-649.
[38]Zhou E,Fu Y,Wei Z,et al.Inhibition of allergic airway inflammation through the blockage of NF-κB activation by ellagic acid in an ovalbumin-induced mouse asthma model[J].Food Funct,2014,5(9):2106-2112.
[39]Bakkourik E,Wullaert A,Haegman M,et al.Adenoviral gene transfer of the NF-κB inhibitory protein abin-1 decreases allergic airway inflammation in a murine asthma model[J].J Biol Chem,2005,280(18):17938-17944.
[40]Krishnamurthy P,Kaplan MH.STAT6 and PARP Family Members in the Development of T Cell-dependent Allergic Inflammation[J].Immune Netw,2016,16(4):201-210.
[41]Mc Cracken JL,Veeranki SP,Ameredes BT,et al.Diagnosis and Management of Asthma in Adults: A Review [J].JAMA,2017,318(3):279-290.
[42]Rayees S,Malik F,Bukhari SI,et al.Linking GATA-3 and interleukin-13:implications in asthma[J].Inflamm Res,2014,63(4):255-265.


[1]焦龙龙,郭悦鹏.初诊哮喘患者的呼出气一氧化氮与大小气道功能的 相关性及临床价值分析[J].医学信息,2018,(06):70.[doi:10.3969/j.issn.1006-1959.2018.06.022]
 JIAO Long-long,GUO Yue-peng.Correlation and Clinical Value Analysis of Exhaled Nitric Oxide and Airway Function in Patients with Newly Diagnosed Asthma[J].Medical Information,2018,(05):70.[doi:10.3969/j.issn.1006-1959.2018.06.022]
 LIU Yu-zhen.Clinical Study of Montelukast in the Treatment of Bronchial Asthma[J].Medical Information,2018,(05):140.[doi:10.3969/j.issn.1006-1959.2018.10.047]
[3]井庆彦.治未病三伏贴对支气管哮喘缓解期患者 冬病夏治的疗效观察[J].医学信息,2018,(17):143.[doi:10.3969/j.issn.1006-1959.2018.17.045]
 JING Qing-yan.Therapeutic Effect of Preventive Treatment of Disease of Sanfu Paster on Summer Treatment of Winter Disease in Patients with Bronchial Asthma[J].Medical Information,2018,(05):143.[doi:10.3969/j.issn.1006-1959.2018.17.045]
[4]赵 静,陈华琴,张 宁,等.血清骨膜蛋白和脂联素联检诊断儿童支气管哮喘价值研究[J].医学信息,2018,(21):71.[doi:10.3969/j.issn.1006-1959.2018.21.019]
 ZHAO Jing,CHEN Hua-qin,ZHANG Ning,et al.Diagnostic Value of Serum Periosteal Protein and Adiponectin in Children with Bronchial Asthma[J].Medical Information,2018,(05):71.[doi:10.3969/j.issn.1006-1959.2018.21.019]
 MENG Lin-fei,HUANG Wei-jian,FENG Meng-jie,et al.Advances in Research on Phenotypes of Chronic Lung Diseases Based on Cluster Analysis[J].Medical Information,2019,(05):44.[doi:10.3969/j.issn.1006-1959.2019.07.015]

更新日期/Last Update: 2019-03-01